Geode Capital Management
TPST icon

Geode Capital Management’s Tempest Therapeutics TPST Stock Holding History

Geode Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Buy
86,990
+42,878
+97% +$103K ﹤0.01% 4027
2025
Q4 		$127K Buy
44,112
+3,088
+8% +$21.8K ﹤0.01% 4044
2025
Q3 		$422K Buy
41,024
+6,288
+18% +$54.6K ﹤0.01% 3681
2025
Q2 		$236K Buy
34,736
+1,402
+4% +$9.97K ﹤0.01% 3822
2025
Q1 		$320K Buy
33,334
+6,082
+22% +$69K ﹤0.01% 3698
2024
Q4 		$296K Buy
27,252
+10,324
+61% +$133K ﹤0.01% 3767
2024
Q3 		$308K Buy
16,928
+5,063
+43% +$104K ﹤0.01% 3758
2024
Q2 		$338K Buy
11,865
+1,705
+17% +$73.8K ﹤0.01% 3722
2024
Q1 		$517K Buy
10,160
+474
+5% +$23.9K ﹤0.01% 3600
2023
Q4 		$554K Buy
9,686
+2,680
+38% +$127K ﹤0.01% 3568
2023
Q3 		$28.5K Sell
7,006
-859
-11% -$8.25K ﹤0.01% 4551
2023
Q2 		$130K Buy
7,865
+2,721
+53% +$68.5K ﹤0.01% 4228
2023
Q1 		$155K Sell
5,144
-34
-0.7% -$746 ﹤0.01% 4162
2022
Q4 		$78K Sell
5,178
-15
-0.3% -$316 ﹤0.01% 4480
2022
Q3 		$117K Buy
5,193
+3,215
+163% +$95.4K ﹤0.01% 4500
2022
Q2 		$54K Sell
1,978
-677
-25% -$26.3K ﹤0.01% 4759
2022
Q1 		$117K Buy
2,655
+13
+0.5% +$590 ﹤0.01% 4600
2021
Q4 		$181K Buy
2,642
+850
+47% +$117K ﹤0.01% 4522
2021
Q3 		$337K Buy
+1,792
New +$349K ﹤0.01% 4209
2021
Q2 		– Sell
-456
Closed -$106K – 4735
2021
Q1 		$106K Hold
456
– – ﹤0.01% 4286
2020
Q4 		$190K Buy
456
+89
+24% +$30.8K ﹤0.01% 3903
2020
Q3 		$116K Sell
367
-335
-48% -$114K ﹤0.01% 3870
2020
Q2 		$241K Sell
702
-33
-4% -$13.2K ﹤0.01% 3609
2020
Q1 		$756K Buy
735
+217
+42% +$316K ﹤0.01% 3123
2019
Q4 		$681K Buy
518
+201
+63% +$283K ﹤0.01% 3407
2019
Q3 		$438K Buy
317
+9
+3% +$14.5K ﹤0.01% 3512
2019
Q2 		$694K Buy
308
+235
+322% +$692K ﹤0.01% 3343
2019
Q1 		$214K Hold
73
– – ﹤0.01% 3720
2018
Q4 		$113K Hold
73
– – ﹤0.01% 3835
2018
Q3 		$156K Hold
73
– – ﹤0.01% 3822
2018
Q2 		$195K Hold
73
– – ﹤0.01% 3723
2018
Q1 		$174K Hold
73
– – ﹤0.01% 3731
2017
Q4 		$300K Sell
73
-5
-6% -$21K ﹤0.01% 3536
2017
Q3 		$322K Hold
78
– – ﹤0.01% 3507
2017
Q2 		$354K Sell
78
-22
-22% -$93.1K ﹤0.01% 3491
2017
Q1 		$549K Buy
100
+6
+6% +$27.9K ﹤0.01% 3275
2016
Q4 		$420K Buy
94
+24
+34% +$299K ﹤0.01% 3330
2016
Q3 		$1.47M Buy
70
+2
+3% +$36.2K ﹤0.01% 2733
2016
Q2 		$1.04M Buy
68
+12
+21% +$274K ﹤0.01% 2887
2016
Q1 		$1.56K Buy
56
+5
+10% +$106K ﹤0.01% 2611
2015
Q4 		$1.47M Buy
51
+2
+4% +$66K ﹤0.01% 2668
2015
Q3 		$1.23M Buy
49
+6
+14% +$404K ﹤0.01% 2756
2015
Q2 		$3.61M Sell
43
-2
-4% -$183K ﹤0.01% 2118
2015
Q1 		$4.55M Buy
45
+9
+25% +$1.2M ﹤0.01% 1911
2014
Q4 		$4.7M Buy
36
+7
+24% +$513K ﹤0.01% 1852
2014
Q3 		$1.39M Buy
29
+7
+32% +$245K ﹤0.01% 2585
2014
Q2 		$598K Buy
22
+1
+5% +$23.6K ﹤0.01% 3074
2014
Q1 		$536K Buy
21
+5
+31% +$142K ﹤0.01% 3122
2013
Q4 		$432K Hold
16
– – ﹤0.01% 3141
2013
Q3 		$462K Hold
16
– – ﹤0.01% 2992
2013
Q2 		$626K Buy
+16
New +$601K ﹤0.01% 2742

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Geode Capital Management's TPST Position: Q1 2026 in Review

Geode Capital Management increased its Tempest Therapeutics (TPST) stake by 97% in Q1 2026, buying an estimated $103K and bringing the position to 86,990 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #4027.

Geode Capital Management first reported a position in TPST in Q2 2013 and has held it in 51 quarters since. The position peaked at $4.7M in Q4 2014. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.

  • Geode Capital Management held 86,990 shares of Tempest Therapeutics worth $143K as of Q1 2026.
  • Geode Capital Management bought 42,878 Tempest Therapeutics shares in Q1 2026, an estimated $103K.
  • Tempest Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4027 holding.
  • Geode Capital Management first reported a position in Tempest Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Geode Capital Management's Tempest Therapeutics position peaked at $4.7M in Q4 2014.
  • 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.